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INTRODUCTION
Growth hormone secretagogues (GHSs) have been consid-
ered as alternatives in the treatment of diseases related to 
growth hormone (GH) deficiency because of their ability to 
release GH in the body.1-3 GHSs enhance the pulsatile release 
of GH in the anterior pituitary gland, resulting in sustained el-
evation of insulin-like growth factor (IGF)-I levels. As GH is a 
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Purpose: Growth hormone secretagogues (GHSs) possess the ability to release growth hormone (GH) in the body. This study 
aimed to investigate the effects of MK-677, an orally active GHS, on somatic growth in rats.  
Materials and Methods: The serum levels of GH were measured after oral administration of MK-677 to confirm GH stimulatory 
effects. Body weight, body length, tibia length, epiphyseal plate width, and serum levels of insulin-like growth factor (IGF)-I were 
measured after oral administration of 4 mg/kg of MK-677 for 6 weeks to investigate growth-promoting effects. 
Results: Oral administration of MK-677 at 4 mg/kg increased peak GH concentrations by 1.8-fold, compared to baseline. Howev-
er, oral administration of MK-677 for 6 weeks did not increase body growth or serum levels of IGF-I. At 6 weeks after treatment, 
the GH response to MK-677 was abolished. Pituitary GH mRNA and hypothalamic GH-releasing hormone mRNA, and GH secre-
tagogue receptor (GHSR) mRNA expression in the pituitary and hypothalamus did not differ between the control and treatment 
group. Somatostatin (SST) mRNA expression in the hypothalamus was markedly increased in the treatment group, whereas SST 
receptor (SSTR)-2 mRNA expression in the pituitary gland was decreased. Protein expression of hypothalamic GHSR, SST, and 
pituitary SSTR-2 showed patterns similar to those for mRNA expression.
Conclusion: Our results suggest that prolonged administration of MK-677 in rats does not promote growth despite the GH stimu-
latory effect of MK-677, which may be related to increased expression of SST in the hypothalamus. Further studies are needed to 
overcome the observed desensitization to GHS. 
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large peptide molecule, it must be injected into subcutaneous 
tissue or muscle to get it into the blood. However, MK-677, an 
orally active non-peptide mimic of GHSs, can stimulate the 
release of GH effectively by intravenous, subcutaneous, intra-
peritoneal, and oral administration.4,5 Growth hormone-re-
leasing peptide (GHRP)-6, which is a synthetic hexapeptide, 
also shows potent GH-releasing activity after intravenous, 
subcutaneous, intranasal, and oral administration in humans. 
MK-677 is a non-peptide spiropiperidine previously shown to 
be functionally and mechanistically indistinguishable in vitro 
and in vivo from the potent peptide GHS GHRP-6.1 MK-677 
has been found to elevate GH levels, as well as IGF-I and cor-
tisol levels, in dogs after oral administration:6 this stimulatory 
effect appears to depend on the presence of an intact pitu-
itary.7 Previous studies in humans demonstrated that daily 
oral administration of MK-677 in healthy older adults,8 GH-
deficient adults9 for 4 weeks, and GH-deficient children10 for 7 
days increased serum GH, IGF-I, and IGF binding protein 
(IGFBP)-3 concentrations. Further, clinical trial studies of MK-
1175
Junghun Lee, et al.
https://doi.org/10.3349/ymj.2018.59.10.1174
677 have been conducted to improve body composition and 
metabolism in older adults11 or to increase bone mass in 
obese young males and older adults.12,13 However, the benefi-
cial effect of MK-677 on growth promotion in children is con-
troversial. The aims of this study were to investigate whether 
oral administration of MK-677 1) stimulates the secretion of 
serum GH and increases the serum levels of IGF-I, 2) enhanc-
es the body length and width of growth plates in rats, and 3) 
influences mRNA expression of GH in the pituitary gland and 
mRNA and protein expression of GH-releasing hormone 
(GHRH), GHS receptor (GHSR), somatostatin (SST), and so-
matostatin receptors (SSTRs) in the hypothalamus. 
MATERIALS AND METHODS
Animals and experimental design
Animals were provided access to regular chow and water ad 
libitum and were maintained at a temperature of 21±2°C and 
humidity of 60±10% on 12-h light/dark cycles. Female 
Sprague-Dawley (SD) rats, approximately 4 weeks of age, in 
each group were used for the experiments. The rats were fast-
ed for 8 h before treatment and provided water ad libitum. 
MK-677 was administered via a stomach tube, and blood sam-
ples were collected from the tail vein during the experiment or 
from the heart after decapitation. Formulations of MK-677 
were prepared at 1 mg/mL in distilled water. Distilled water 
was administered at 4 mL/kg as a placebo. All animal studies 
were approved by the Animal Care and Use Committee of the 
Yonsei University College of Medicine (No. 2013-0095). 
To determine whether oral administration of MK-677 can 
stimulate GH secretion in rats, MK-677 was administered at 2 
or 4 mg/kg via the stomach tube. Distilled water was adminis-
tered at the same volume as a control. Blood samples were 
collected from the tail vein at 0, 30, 60, 90, and 120 min after 
treatment. Plasma was harvested by centrifugation and stored 
in -70˚C for determination of GH. The same experiment was 
conducted after treatment with MK-677 for 6 weeks to deter-
mine whether the GH stimulatory effect was sustained after 
long-term use of MK-677.
MK-677 was administered at 4 mg/kg via the stomach tube 
between 08:00 and 10:00 for 6 weeks. Distilled water was ad-
ministered at 4 mL/kg as a control. To evaluate the growth-
promoting effect of MK-677, body weight and body length 
were measured daily. The body length of rats was measured 
as the length from the nose to the anus. Blood samples were 
collected from the tail vein every 2 weeks for determination of 
IGF-I. The width of the tibia growth palate was measured after 
decapitation at 6 weeks after treatment. Right tibia tissues 
were fixed in 4% paraformaldehyde for 24 h. Decalcification 
was performed with an EDTA-G solution (14.5 g EDTA, 1.25 g 
NaOH, and 15 mL glycerol dissolved in distilled water, pH 7.3). 
The solution was then brought to 100 mL and stored for 10−14 
days at 4°C. The fixed and decalcified tibia was embedded in 
paraffin and sectioned at 5 μm. Paraffin bone sections were 
stained with hematoxylin and eosin (Sigma, St. Louis, MO, 
USA) according to the manufacturer’s instructions.
To determine whether MK-677 can alter GH, GHRH, GHSR, 
SST, and SSTR mRNA and protein expression, rats were sacri-
ficed by decapitation at 6 weeks after treatment. The pituitary 
gland and hypothalamus were collected and frozen for analy-
sis of mRNA expression of GH, GHRH, GHSR, SST, and SSTR 
by real-time polymerase chain reaction (RT-PCR) and protein 
expression by Western immunoblotting. 
Hormone analysis 
Blood samples were collected in serum-separating tubes and 
centrifuged for 15 min at 3000 rpm at 4°C. Separated sera were 
stored at -20°C until ready for analysis. All hormone analyses 
were performed by Enzyme-linked Immunosorbent Assay 
(ELISA). GH was determined by ELISA (E-EL-R0029, Elab-
science Biotech, Wuhan, China) with a sensitivity of 0.188 ng/
mL, intra-assay coefficient of variation of 3.87−5.15%, and in-
ter-assay coefficient of variation of 7.04−8.45%. Sera were di-
luted 10-fold with reference standard and sample diluent. 100 
μL of sample was added to micro ELISA plate wells and incu-
bated for 90 min at 37°C. After the solution was removed, 100 
μL of biotinylated detection Ab working solution was added. 
The plates were incubated for 1 hour at 37°C and washed with 
350 μL of wash buffer three times. Then, horseradish peroxi-
dase conjugate working solution was added. After washing 
the wells five times with buffer, substrate reagent was added 
to each well and reacted by blocking light for about 15 min at 
37°C. Finally, stop solution was added to the ELISA plates, and 
absorbance was measured with a micro-plate reader set to 
450 nm. IGF-I was determined by ELISA (E-EL-R0010, Elab-
science Biotech) with a sensitivity of 18.75 pg/mL, intra-assay 
coefficient of variation of 3.4−5.7%, and inter-assay coefficient 
of variation of 5.7−7.9%. The IGF-I ELISA experiment was per-
formed according to the manufacturer’s instructions. Sera 
were diluted 100-fold with reference standard and sample di-
luent. Absorbance was measured on a spectrophotometer at 
450 nm wavelength.
Western immunoblotting
Antibodies against GHSR (E-AB-33767), SST (E-AB-32939), and 
SSTR-2 (E-AB-36114) were purchased from Elabscience Bio-
tech. SSTR-5 antibody was purchased from Abcam (ab156864, 
Cambridge, MA, USA), and GAPDH was purchased from Cell 
Signaling Technology (#2118, Danvers, MA, USA), respectively. 
Protein from tissue was homogenized using RIPA buffer (Ther-
mo Scientific, Waltham, MA, USA) with protease inhibitor. The 
samples were incubated on ice for 30 min and centrifuged at 
13000 rpm for 15 min. After centrifugation, the supernatant 
was collected in a new tube. Protein concentrations were de-
termined by a BCA assay (Pierce, Rockford, IL, USA). Equal 
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amounts of protein (50 μg) were electrophoresed on a 15% 
SDS-PAGE gel and transferred to a PVDF membrane. Subse-
quently, the blots were blocked with 5% nonfat dry milk for 1 
hour and incubated with first antibody (dilution, 1:1000) over-
night at 4°C. Membranes were washed three times for 5 min 
with PBST (0.2% Tween 20) and incubated with secondary an-
tibody (dilution, 1:3000) for 1 hour. Blots were washed with 
PBST three times for 10 min. Protein expression was detected 
using an ECL (Amersham Biosciences, Piscataway, NJ, USA) 
solution according to the manufacturer’s instructions. GAPDH 
was used as a sample loading control.
RT-PCR analysis 
Total RNA was isolated from cells using TRIzol reagent (Invit-
rogen, Carlsbad, CA, USA). Five micrograms of total RNA was 
subjected to reverse transcription using the SuperscriptTM III 
first-strand synthesis system (Invitrogen) according to the 
manufacturer’s instructions. RT-PCR was conducted in 20 μL 
of reaction mixture containing cDNA, TaqMan primer pairs, 
and TaqMan universal PCR master mix (Applied Biosystems, 
Foster City, CA, USA). The primer pairs were obtained from 
Applied Biosystems (Rn01495894 for GH, Rn00580832 for 
GHRH, Rn00821417 for GHSR, Rn00561967 for SST, 
Rn01464950 for SSTR-2, Rn02535169 for SSTR-5, and 
Rn01775763 for GAPDH). Amplification was performed in 
duplicate with the ABI 7300 system (Applied Biosystems) with 
the following profile: 50°C for 2 min, 95°C for 10 min, and 40 
cycles of 95°C for 15 s, and 60°C for 1 min. The gene expres-
sion in each sample was expressed in terms of the threshold 
cycle (Ct) normalized to GAPDH (∆Ct). The ΔCt values were 
compared between samples from MK-677 treated tissues (hy-
pothalamus and pituitary gland) and control samples to cal-
culate ΔΔCt. The final comparison of the transcript ratios be-
tween samples is given as 2-ΔΔCt.14
Statistical analysis 
All statistical calculations were performed using SAS version 9.2 
(SAS Institute Inc., Cary, NC, USA). Two-tailed t test was used 
to test for differences between the treatment group and con-
trols. p values <0.05 were considered statistically significant. 
RESULTS
GH response to MK-677 at baseline and at 6 weeks  
after treatment
Serum GH concentrations after oral administration of 2 and 4 
mg/kg of MK-677 or control at baseline are shown in Fig. 1A. 
Oral administration of MK-677 at 4 mg/kg significantly in-
creased GH concentrations with a 1.8-fold increase in peak GH 
concentration (45.7 ng/mL), whereas administration of distilled 
water did not increase GH concentrations. The GH area under 
the curve (AUC) showed a similar significant increase after ad-
ministration of 4 mg/kg of MK-677, compared to the distilled 
water control group (1090 vs. 206 ng/min/mL, p<0.05). The 
peak GH concentration was observed at 60 min after treatment 
and returned to near-pretreatment levels by 120 min. The in-
creased response of GH after administration of MK-677 was 
abolished in animals treated with MK-677 for 6 weeks. Oral ad-
ministration of MK-677 at 4 mg/kg in rats treated with MK-677 
for 6 weeks did not increase GH concentrations (Fig. 1B). 
   
Efficacy of oral administration of MK-677 for 6 weeks
The treatment group showed no increase in body weight, 
body length, and width of the tibia growth plate after 6 weeks 
of MK-677 treatment, compared to the control group (Fig. 2). 
Serum IGF-I levels at 2, 4, and 6 weeks were not changed, 
compared to those at baseline, and did not differ between the 
treatment group and control group at each time point (Fig. 3). 
   
Effect of MK-677 on mRNA and protein expression of 
GH, GHRH, GHSR, SST, and SSTRs in the pituitary 
gland and hypothalamus
Pituitary GH and hypothalamic GHRH mRNA levels did not 
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differ between the control and treatment groups (Fig. 4A and 
B). Pituitary and hypothalamic GHSR mRNA expression did 
not differ between the control and treatment groups (Fig. 4C). 
SST mRNA expression in the hypothalamus was markedly in-
creased in the treatment group, compared to the control 
group (Fig. 4D). In addition, SSTR-2 mRNA expression in the 
pituitary gland was decreased in the treatment group, com-
pared to the control group (Fig. 4E), whereas SSTR-5 mRNA 
expression in the pituitary gland was not different between 
two groups (Fig. 4F). Protein expression of hypothalamic 
GHSR, SST, and pituitary SSTR-2 and -5 showed the same pat-
terns as those for mRNA expression (Fig. 4G).  
DISCUSSION 
Secretion of GH in the pituitary gland is regulated by GHRH 
and SST in the hypothalamus. GHRH stimulates the release of 
GH through GHRH receptor, whereas SST represses the re-
lease of GH through SSTR.15 In 1977, new synthetic peptides 
with GH-releasing ability were discovered.16 These new com-
pounds were enkephalin analogs, with weak GH-releasing ac-
tivity in vitro and inactivity in vivo. Subsequently, more potent 
GHRPs were developed by chemical modifications.17 GHRPs 
have no sequential homology with GHRH and are more effec-
tive for inducing GH release even at the same dose of GHRH.18 
Many studies have found that GHRPs have GH releasing ac-
tivity in several species via their own receptors known as GHS 
receptor, not GHRH receptor.19 Recently, to overcome the lim-
it of low oral bioavailability, peptide-mimicking and non-pep-
tidyl GHS, which can be administered orally, were devel-
oped.4,5,20 SM-130686, an orally active non-peptidyl GHS, was 
developed and was confirmed to have GH-releasing activity. 
In rats, SM-130686 was found to enhance GH secretion and 
body weight gain.20 Another non-peptidyl GHS, ibutamoren 
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mesylate (MK-677), was reported to stimulate the release of 
GH and to show an oral bioavailability of more than 60%.4,18 
Oral administration of MK-677 was also shown to elevate GH 
levels, as well as IGF-I and cortisol levels, in dogs6 and that 
this stimulatory effect is dependent on the presence of an in-
tact pituitary.7 In humans, daily oral administration of MK-677 
in healthy older adults,8 GH-deficient adults,9 or GH-deficient 
children10 increases serum GH, IGF-I, and IGFBP-3 concen-
trations, suggesting that these GHSs are potential treatments 
for growth disorders. However, repeated administration of 
GHRP has been reported to desensitize its stimulatory effect 
on GH secretion, and there have been no studies of the growth 
promoting effect after its long-term use, thereby limiting clini-
cal application.21
In our study, oral administration of 4 mg/kg of MK-677 in-
creased the peak concentrations of serum GH by 1.8-fold, 
compared to basal levels, and GH AUC was significantly in-
creased, suggesting that oral administration of MK-677 has 
GH-releasing activity. However, the growth promoting effect 
assessed by measuring the body weight, body length, width of 
tibia growth plate, and serum level of IGF-I was not observed 
after oral administration of 4 mg/kg of MK-677 for 6 weeks. 
The desensitization phenomenon of GHRP has been reported 
previously.22-26 In an animal study using transgenic growth-re-
tarded rats, infusion of GHRP-6 for 7 days produced a dose-
dependent increase in body weight gain and accelerated skel-
etal growth.26 However, this growth promoting effect was 
observed only in the group infused with GHRP-6 at 3-h pulses. 
Continuous infusion of GHRP-6 was only effective in acceler-
ating growth for the first 2 days of infusion, suggesting that the 
growth response with continuous infusion is transient be-
cause of desensitization. In normal female rats, continuous 
infusion of GHRP has been reported to induce tachyphylaxis 
after an initial increase in growth velocity, suggesting that 
continuous infusion of GHRP induces desensitization.27 Re-
peated administration of hexarelin at 120-min intervals de-
creased the magnitude of the GH response in healthy adult 
males.25 In our study, oral administration of MK-677 did not 
stimulate GH secretion after treatment for 6 weeks, suggesting 
that the initial GH stimulatory effect of MK-677 was abolished 
in animals treated with MK-677 for 6 weeks. 
The mechanisms of GHRP desensitization after continuous 
infusion or long-term use have not been fully clarified. Many 
studies have demonstrated that continuous infusion of GHRP 
did not alter GH stores and GHRH receptor expression in the 
pituitary gland or GHRH expression in the hypothalamus.22,23,27 
The most direct and probable mechanism is the down regula-
tion of GHSR in the pituitary gland and hypothalamus after 
treatment with GHRP. However, previous studies demonstrat-
ed that continuous infusion of GHRP-6 did not alter hypotha-
lamic GHSR expression in arcuate and ventromedial nuclei28 
or even increase arcuate GHSR expression.26 The results of our 
study also showed that oral administration of MK-677 for 6 
weeks did not alter mRNA expressions of pituitary GH and hy-
pothalamic GHRH and GHSR in the pituitary gland and hypo-
thalamus or protein expression of GHSR in the hypothalamus. 
Another possible mechanism of desensitization induction is 
increased expression of SST in the periventricular nucleus fol-
lowing continuous infusion of GHRP.26,29 In our study, mRNA 
and protein expression of SST in the hypothalamus was mark-
edly increased after treatment with MK-677 for 6 weeks, which 
inhibits GHRH- and GHS-induced GH secretion. In contrast, 
mRNA and protein expression of SSTR-2 in the pituitary gland 
was decreased, which may have resulted from elevated expres-
sion of SST in the hypothalamus. 
In conclusion, oral administration of the GHS MK-677 stimu-
lates GH secretion. However, prolonged oral administration for 
6 weeks does not promote growth and abolishes the GH stimu-
latory effect of MK-677, potentially resulting from increased ex-
pression of SST in the hypothalamus. Further studies are need-
ed to develop a strategy for overcoming the increased expression 
of SST, thereby leading to growth promotion. 
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